
    
      Initial randomization is Tigan or Placebo (3:1) with phased withdrawal of Tigan to Placebo
      after 4 and 8 weeks. Subjects completing 4 weeks Tigan re-randomized to Tigan or Placebo
      (2:1) with patients completing 8 weeks Tigan re-randomized to receive Tigan or Placebo (1:1).
      Subjects randomized to Placebo over the previous 4 weeks assigned to continue on Placebo for
      the remainder of the study.
    
  